Roche Pharmaceutical Development and Sales Overview

Lucentis Global sales CHFbn CER growth -25% Regional sales CER growth 1.5 1.2 0.9 0.6 0.3 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 800m • Impacted by switching to Vabysmo, entrance of biosimilars and order patterns CER-Constant Exchange Rates US -25% Roche 163

View entire presentation